Subclinical hyperthyroidism should almost always be treated when your TSH drops below 0.1 mIU/L, especially if you’re over 65. When TSH falls in the mildly low range (0.1 to 0.4 mIU/L), the decision depends on your age, symptoms, and risk factors for heart disease and bone loss. Understanding where you fall on this spectrum is the key to knowing whether treatment makes sense for you.
What Subclinical Hyperthyroidism Actually Means
Subclinical hyperthyroidism means your TSH (the hormone that tells your thyroid to work) is below the normal range of 0.45 to 4.5 μU/mL, but your actual thyroid hormone levels are still normal. Your thyroid is running slightly hot, enough to suppress the signal from your brain, but not enough to push thyroid hormones out of range on a blood test.
Clinicians now split this into two grades that carry very different risks:
- Grade I (mild): TSH between 0.1 and 0.4 mIU/L
- Grade II (severe): TSH below 0.1 mIU/L
That 0.1 cutoff is the single most important number in deciding whether you need treatment. Grade II carries substantially higher risks for your heart and bones, and guidelines broadly agree it warrants intervention. Grade I is more of a gray zone.
When Treatment Is Clearly Recommended
If your TSH is persistently below 0.1 mIU/L, most major guidelines recommend treatment regardless of whether you feel symptoms. The word “persistently” matters. A single low reading can result from temporary illness, medication effects, or lab variation, so your doctor will typically confirm the result with a repeat test before committing to treatment.
The case for treating Grade II subclinical hyperthyroidism is strongest in two groups: people over 65 and people with existing heart disease or osteoporosis. ATA/AACE guidelines specifically recommend treatment for anyone over 65 whose TSH is persistently below 0.1 mIU/L. A 2025 review in a leading endocrinology journal reaffirmed that position, citing the association between very low TSH and both cardiovascular risk and bone density loss in older adults.
For younger people with TSH below 0.1, treatment is still generally recommended, though the urgency is lower if you have no other risk factors.
The Gray Zone: TSH Between 0.1 and 0.4
This is where the decision gets individualized. Guidelines agree that in mild subclinical hyperthyroidism, other risk factors should be weighed before choosing treatment or watchful waiting. The factors that tilt the scale toward treatment include:
- Age over 65: Guidelines say treatment “can be considered” for older adults even in this mild range.
- Heart rhythm problems: Any history of atrial fibrillation or palpitations strengthens the case for treatment.
- Osteoporosis or high fracture risk: Particularly relevant for postmenopausal women.
- Symptoms: Rapid heartbeat, tremor, anxiety, unexplained weight loss, or heat intolerance, even if subtle, can indicate your body is responding to the excess thyroid activity.
- A known thyroid nodule: Autonomously functioning nodules rarely resolve on their own, making progression to overt hyperthyroidism more likely.
If you’re under 65, have no symptoms, no heart disease risk, and no bone concerns, monitoring without treatment is a reasonable choice. Your doctor will recheck your TSH periodically to watch for progression.
Why Untreated Low TSH Isn’t Harmless
The reason treatment thresholds exist at all is that even “subclinical” thyroid overactivity takes a measurable toll over time, particularly on the heart and skeleton.
Heart Rhythm Risk
A meta-analysis of five studies found that subclinical hyperthyroidism nearly doubles the risk of developing atrial fibrillation, with a pooled risk ratio of 1.99. Atrial fibrillation is a chaotic heart rhythm that raises stroke risk and can lead to heart failure over time. An earlier systematic review by Collet and colleagues reported a somewhat more conservative but still significant hazard ratio of 1.68. Either way, the risk increase is substantial enough that it drives treatment decisions, especially in older adults who already face higher baseline odds of heart rhythm problems.
Bone Density and Fractures
Thyroid hormones accelerate bone turnover. When thyroid activity runs high for months or years, bone breaks down faster than it rebuilds. A large analysis published in JAMA Network Open found that people with subclinical hyperthyroidism had a 34% higher risk of fracture compared to those with normal thyroid function. This effect is most clinically meaningful in postmenopausal women, who are already losing bone density due to declining estrogen.
What Treatment Looks Like
Treatment for subclinical hyperthyroidism depends on the underlying cause. The two main options are antithyroid medication and radioactive iodine.
Antithyroid medication is often the first step, particularly for milder cases or when the cause is Graves’ disease. Treatment typically starts at a moderate dose that’s gradually reduced over months as thyroid function normalizes. In one long-term study of patients with overactive thyroid nodules, the average daily dose dropped from 14 mg at the start to about 4 mg after several years of maintenance. The medication works by directly blocking thyroid hormone production.
Radioactive iodine is a more permanent solution, often used when a thyroid nodule is autonomously producing hormone or when long-term medication isn’t practical. It destroys overactive thyroid tissue. The tradeoff is that some people end up with an underactive thyroid afterward and need lifelong thyroid hormone replacement. In one comparative study, patients treated with radioactive iodine spent a larger percentage of their follow-up period in a subclinically hyperthyroid state (about 17% of the time) compared to those on medication (about 3%), suggesting medication offers tighter control in the short term.
Surgery is a third option, typically reserved for large goiters or cases where the other treatments aren’t suitable.
Monitoring If You’re Not Treating
If you and your doctor decide to hold off on treatment, the plan isn’t to ignore it. Repeat TSH testing is essential to track whether your levels are stable, improving, or worsening. The exact testing interval depends on your situation, but the goal is to catch any progression toward overt hyperthyroidism before it causes damage.
Some causes of subclinical hyperthyroidism are transient. Thyroiditis (inflammation of the thyroid) can temporarily suppress TSH for weeks or months before resolving. Excess iodine intake from supplements or contrast dye used in medical imaging can do the same. In these cases, the low TSH may normalize without any intervention. Autonomous thyroid nodules, on the other hand, tend to persist or worsen over time, which is why the underlying cause matters when deciding between treatment and monitoring.
If you’re in the mild category and your TSH remains stable in the 0.1 to 0.4 range over repeated tests, continued monitoring is reasonable as long as your risk profile hasn’t changed. A new diagnosis of osteoporosis, a shift into menopause, or reaching age 65 can all be reasons to revisit the treatment conversation.